Renaissance Technologies
AEGR

Renaissance Technologies’s Aegerion Pharmaceuticals AEGR Stock Holding History

Renaissance Technologies’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,716,200
Closed -$5.1M – 3645
2016
Q3 		$5.1M Buy
1,716,200
+346,700
+25% +$601K 0.01% 1589
2016
Q2 		$2.04M Buy
1,369,500
+593,071
+76% +$1.36M ﹤0.01% 2183
2016
Q1 		$2.87M Buy
776,429
+650,529
+517% +$4.03M 0.01% 2001
2015
Q4 		$1.27M Sell
125,900
-106,900
-46% -$1.29M ﹤0.01% 2348
2015
Q3 		$3.17M Buy
232,800
+73,225
+46% +$1.3M 0.01% 1692
2015
Q2 		$3.03M Buy
+159,575
New +$3.45M 0.01% 1781
2014
Q4 		– Sell
-89,000
Closed -$2.97M – 3249
2014
Q3 		$2.97M Buy
89,000
+12,500
+16% +$388K 0.01% 1454
2014
Q2 		$2.46M Buy
+76,500
New +$2.85M 0.01% 1620
2013
Q4 		– Sell
-52,800
Closed -$4.53M – 3142
2013
Q3 		$4.53M Buy
+52,800
New +$4.48M 0.01% 1211

Renaissance Technologies's AEGR Position: Q4 2016 in Review

Renaissance Technologies sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 1,716,200 shares — an estimated $5.1M sold.

Renaissance Technologies first reported a position in AEGR in Q3 2013 and held it in 9 quarters. The position peaked at $5.1M in Q3 2016. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • Renaissance Technologies reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Renaissance Technologies sold 1,716,200 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $5.1M.
  • Renaissance Technologies first reported a position in Aegerion Pharmaceuticals in Q3 2013 and held it in 9 quarters.
  • Renaissance Technologies's Aegerion Pharmaceuticals position peaked at $5.1M in Q3 2016.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.